Intervention vs Control Group: Number Treated for Microbiologically-confirmed TB Within 14 Days After Presentation to the Health Center for TB Evaluation

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measure	Value	95% interval, lower	95% interval, upper	Method	Source
Risk in group 1	0.0617	0.0556	0.0683	wilson	ClinicalTrials.gov
Risk in group 2	0.0432	0.0379	0.0491	wilson	ClinicalTrials.gov
Risk difference, group 1 minus group 2	0.0185	0.0101	0.027	newcombe hybrid score	ClinicalTrials.gov
Risk ratio, group 1 over group 2	1.43	1.21	1.69	log	ClinicalTrials.gov
Odds ratio, group 1 over group 2	1.46	1.22	1.73	log	ClinicalTrials.gov
Number needed to treat, for one more participant with the outcome on Intervention than on Control Group	54	37.1	99.5	from the risk difference interval	ClinicalTrials.gov

Groups 2

Group 2 names the comparator: control.

Group	Title	Description	With the outcome	Analysed	ClinicalTrials.gov code	Source
Group 1	Intervention	Onsite molecular testing for TB with GeneXpert + process redesign to facilitate same-day TB diagnosis and treatment + performance feedback~GeneXpert: Onsite molecular testing with GeneXpert as a replacement for microscopy~Process re-design: Research and Uganda NTLP staff will engage health center staff in a discussion of how to re-organize clinical, laboratory and pharmacy services to enable same-day TB diagnosis and treatment.~Performance Feedback: Feedback of TB diagnostic evaluation quality indicators to health center staff	342	5,546	OG001	ClinicalTrials.gov
Group 2	Control Group	Onsite ZN or LED fluorescence microscopy + hub-based GeneXpert testing per existing protocols	220	5,098	OG000	ClinicalTrials.gov

Outcome 5

Field	Value	Source
Type	PRIMARY	ClinicalTrials.gov
Title	Number Treated for Microbiologically-confirmed TB Within 14 Days After Presentation to the Health Center for TB Evaluation	ClinicalTrials.gov
Description	Effectiveness outcome.	ClinicalTrials.gov
Time frame	Within 14 days after presentation to the health center for tuberculosis evaluation	ClinicalTrials.gov
Population		ClinicalTrials.gov

Trial 8

Field	Value	Source
Title	GeneXpert Performance Evaluation for Linkage to Tuberculosis Care	ClinicalTrials.gov
NCT number	NCT03044158	ClinicalTrials.gov
Phases	NA	ClinicalTrials.gov
Conditions	Tuberculosis, Pulmonary, Rifampicin Resistant Tuberculosis	ClinicalTrials.gov
Interventions	GeneXpert I, Process re-design, Performance Feedback	ClinicalTrials.gov
Lead sponsor	University of California, San Francisco	ClinicalTrials.gov
Results first posted	2025-02-18	ClinicalTrials.gov
Results on ClinicalTrials.gov	https://clinicaltrials.gov/study/NCT03044158?tab=results	ClinicalTrials.gov

Source 4

Field	Value	Source
Release	trial-comparisons-2026-03-23-0.1.0	ClinicalTrials.gov
Release manifest SHA-256	f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57	ClinicalTrials.gov
AACT copy	2026-03-23	ClinicalTrials.gov
Tables read	outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet	ClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.